<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="189">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01224483</url>
  </required_header>
  <id_info>
    <org_study_id>2010-02-048</org_study_id>
    <nct_id>NCT01224483</nct_id>
  </id_info>
  <brief_title>Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients</brief_title>
  <official_title>Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Patients With PNH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Paroxysmal nocturnal hemoglobinuria (PNH) is a hematopoietic stem cell disorder in which
      unregulated activation of the complement system leads to significant ischemic morbidities
      with shortened lifespan.  Life-threatening thromboembolism (TE) is the most feared
      complication of PNH, accounting for up to 45% of patient deaths.  It is estimated that 40%
      of PNH patients experience a clinically evident TE and 60% of patients without clinically
      diagnosed TE demonstrate TE by high-sensitivity MRI, indicating the ongoing thrombotic risk
      in most patients with PNH. Much of these data come from PNH patients from European descent.
      To understand the impact of TE in patients with PNH from non-European regions, we performed
      this study to evaluate the clinical characteristics of Korean patients with PNH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the clinical characteristics in Korean PNH patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective:  Retrospective</study_design>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Hemoglobinuria, Paroxysmal</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Korean PNH patients: diagnosis confirmed by Ham's test or Flow cytometry
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis confirmed by Ham's test or Flow cytometry Patients have any Flow cytometry
             data

        Exclusion Criteria:

          -  Patients have no Flow cytometry data
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Ho Jang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Hematology Oncology, Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Ho Jang, M.D.</last_name>
      <phone>82-2-3410-0918</phone>
      <email>smcjunhojang@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <lastchanged_date>October 19, 2010</lastchanged_date>
  <firstreceived_date>October 18, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Jun Ho Jang</name_title>
    <organization>Aplastic Working Party, The Korean Society of Hematology</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
</clinical_study>
